HighTower Advisors’s Immuneering IMRX Stock Holding History

HighTower Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$692K	Buy	131,286 +19,962	+18%	+$102K	﹤0.01%	2450
2025 Q4	$733K	Sell	111,324 -21,135	-16%	-$136K	﹤0.01%	2338
2025 Q3	$927K	Sell	132,459 -3,501	-3%	-$18.2K	﹤0.01%	2163
2025 Q2	$458K	Buy	135,960 +52,000	+62%	+$89.1K	﹤0.01%	2598
2025 Q1	$128K	Buy	83,960 +12,600	+18%	+$22.9K	﹤0.01%	3310
2024 Q4	$157K	Buy	71,360 +18,000	+34%	+$37.3K	﹤0.01%	3264
2024 Q3	$132K	Buy	53,360 +9,400	+21%	+$13.7K	﹤0.01%	3247
2024 Q2	$57K	Buy	+43,960	New	+$72.3K	﹤0.01%	3287
2024 Q1	–	Sell	-23,960	Closed	-$176K	–	3817
2023 Q4	$176K	Hold	23,960	–	–	﹤0.01%	3051
2023 Q3	$184K	Buy	+23,960	New	+$220K	﹤0.01%	2942

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HighTower Advisors's IMRX Position: Q1 2026 in Review

HighTower Advisors increased its Immuneering (IMRX) stake by 18% in Q1 2026, buying an estimated $102K and bringing the position to 131,286 shares worth $692K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

HighTower Advisors first reported a position in IMRX in Q3 2023 and has held it in 10 quarters since. The position peaked at $927K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

HighTower Advisors held 131,286 shares of Immuneering worth $692K as of Q1 2026.
HighTower Advisors bought 19,962 Immuneering shares in Q1 2026, an estimated $102K.
Immuneering made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2450 holding.
HighTower Advisors first reported a position in Immuneering in Q3 2023 and has held it in 10 quarters since.
HighTower Advisors's Immuneering position peaked at $927K in Q3 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.